Evidence map›Paper›PMID 25330161›Full record

Trial reportPloS one2014

Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.

Christine Danel, Mathieu Kabran, André Inwoley, Anani Badje, Jean Louis Herrmann, Raoul Moh, Jérôme Lecarrou, Delphine Gabillard, Jean Baptiste Ntakpe, Nina Deschamps and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00495651 (Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00495651 phase3completednot on this map

Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)

TypeinterventionalSponsorFrench National Agency for Research on AIDS and Viral HepatitisRan2008 to 2015Enrolled2,073ConditionsHIV Infections, TuberculosisArmsAntiretroviral medications, Antiretroviral medications+Isoniazid prophylaxis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Review
  4. QuantiFERON-TB Gold In-Tube test in active tuberculosis patients and healthy adults.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018
    Article
  5. Mycobacterium tuberculosis: 2014 Clinical trials in review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christine DanelINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
Mathieu KabranCeDReS, CHU Treichville, Abidjan, Côte d'Ivoire.
André InwoleyPAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; CeDReS, CHU Treichville, Abidjan, Côte d'Ivoire.
Anani BadjeINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
Jean Louis HerrmannService de Bactériologie, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris, Garches, France; EA3647, Université de Versailles St Quentin en Yvelines, Montigny le Bretonneux, France.
Raoul MohINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France; Service des Maladies Infectieuses et Tropicales, CHU Treichville, Abidjan, Côte d'Ivoire.
Jérôme LecarrouINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
Delphine GabillardINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
Jean Baptiste NtakpeINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
Nina DeschampsPAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire.
Eric OuattaraINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.
Christian PerronneDépartement de Maladies Infectieuses et Tropicales, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris, Garches, France.
Serge EholieINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France; Service des Maladies Infectieuses et Tropicales, CHU Treichville, Abidjan, Côte d'Ivoire.
Xavier AnglaretINSERM, Centre INSERM U897, Bordeaux, France; PAC-CI Program, CHU Treichville, Abidjan, Côte d'Ivoire; ISPED, Bordeaux University, Bordeaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) test for active tuberculosis (TB) in HIV adults, and its variation over time in patients on antiretroviral therapy (ART) and/or isoniazide preventive therapy (IPT).

methodsTransversal study and cohort nested in the Temprano ANRS 12136 randomized controlled trial assessing benefits of initiating ART earlier than currently recommended by World Health Organization, with or without a 6-month IPT. Performance of QFT-GIT for detecting active TB at baseline in the first 50% participants, and 12-month incidence of conversion/reversion in the first 25% participants were assessed. QFT-GIT threshold for positivity was 0.35 IU/ml.

resultsAmong the 975 first participants (median baseline CD4 count 383/mm3, positive QFT-GIT test 35%), 2.7% had active TB at baseline. QFT-GIT sensitivity, specificity, positive and negative predictive value for active TB were 88.0%, 66.6%, 6.5% and 99.5%. For the 444 patients with a second test at 12 months, rates for conversion and reversion were 9.3% and 14%. Reversion was more frequent in patients without ART and younger patients. IPT and early ART were not associated with reversion/conversion.

conclusionA negative QFT-GIT could rule out active TB in HIV-infected adults not severely immunosuppressed, thus avoiding repeated TB testing and accelerating diagnosis and care for other diseases.

trial registrationClinicalTrials.gov NCT00495651.

Indexed as

CD4 Lymphocyte CountEnzyme-Linked Immunosorbent AssayAdultAnti-HIV AgentsCote d'IvoireFemaleFollow-Up StudiesHIV InfectionsHumansInterferon-gammaIsoniazidMaleTuberculosisAnti-HIV AgentsInterferon-gammaIsoniazid

Identifiers

PMID25330161
PMCPMC4199568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.